WO2000003725A1 - Method for identifying and confirming consistent bio-functionality of natural compositions - Google Patents
Method for identifying and confirming consistent bio-functionality of natural compositions Download PDFInfo
- Publication number
- WO2000003725A1 WO2000003725A1 PCT/US1999/015957 US9915957W WO0003725A1 WO 2000003725 A1 WO2000003725 A1 WO 2000003725A1 US 9915957 W US9915957 W US 9915957W WO 0003725 A1 WO0003725 A1 WO 0003725A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- simulated
- dietary supplement
- preparation
- natural composition
- digestion
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/5055—Cells of the immune system involving macrophages
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/555—Interferons [IFN]
- G01N2333/57—IFN-gamma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Definitions
- the present invention relates to a method for assessing the functional biological activity of natural products in the forms of raw material and as finished products as consumed, and the natural products subjected to such method.
- Natural products that are used as dietary supplements are not typically considered to be drugs, yet the consumer frequently expects many of the same properties, efficacy and safety, from natural products that are expected of drugs.
- Pharmaceutical agents (drugs) designed for specific treatment of disease are regulated by the Food and Drug Administration (FDA) and consist of a single or limited and defined mixture of active ingredients. Once a drug compound has been selected, formulated, and then proven safe and efficacious for the disease aimed to be treated as designated by FDA guidelines, the product needs only to be assayed only to assure proper content of the active compound. Effectiveness to the physician and consumer is then governed by the history of the compounds proven clinical effectiveness.
- DHEA Dietary Supplement Health and Education Act
- FDCA Federal Food, Drug and Cosmetic Act
- the present invention employs a functional approach to testing and assessing the quality of the complex mixtures which characterize natural compositions.
- the present invention relates to a method for evaluating the biofunctionality of a natural composition or extract which comprises subjecting the natural composition to simulated digestion, simulated absorption or both to obtain a preparation of said natural composition, determining the presence or absence of one or more components or biological activities in said preparation, and correlating the presence or absence of said one or more components or biological activities in said preparation to the biofunctionality of said natural composition or extract. Simulated digestion and simulated absorption can be carried out sequentially or concurrently.
- Simulated digestion can be simulated gastric digestion or simulated intestinal digestion or can be a combination of both. Simulated digestion is performed in a gastric fluid which is acidic, preferably around pH 1.2, and which may also comprise digestive enzymes which are active under acidic conditions or in an intestinal fluid which is neutral, preferably about pH 7.4 which may also comprise digestive enzymes which are active under neutral conditions.
- a gastric fluid which is acidic, preferably around pH 1.2, and which may also comprise digestive enzymes which are active under acidic conditions or in an intestinal fluid which is neutral, preferably about pH 7.4 which may also comprise digestive enzymes which are active under neutral conditions.
- Simulated absorption involves transport of components or biological activities across a membrane for the purpose of simulating bioavailability.
- the membrane is a monolayer of Caco-2 cells. It is an object of the present invention to provide a system of assays for any given natural composition wherein the system is specifically tailored to assess the relevant biofunctionality of that composition.
- the present invention provides assay methods that assess the expected in vivo biofunctionality of a natural composition and thus, assess the usefulness of the natural composition for treatment of a selected pathological condition or as a dietary supplement for human consumption useful in maintaining healthy structure and function.
- Useful assays can also include assays which define or measure undesired side effects that may be associated with a natural composition.
- the invention is further directed to a dietary supplement comprising a natural composition, having substantial batch-to-batch compositional consistency, said compositional consistency evaluated by a method comprising subjecting a sample of the dietary supplement or the natural composition to simulated digestion, simulated absorption or both to obtain a preparation of said sample, determining the presence of one or more components in said preparation, and correlating the presence of one or more components with compositional consistency.
- compositional consistency is meant substantial uniform batch-to-batch biofunctionality of at least one desired active component or biological activity.
- Another aspect of the invention is a system of testing which is useful for the establishment of standards for natural compositions as well as for assuring the quality and consistency of natural dietary supplements. Rather than attempting only to identify and quantify the active components of any given complex natural composition as consumed, the system of testing is designed to assess the overall biofunctionality of that composition as consumed, and relies on tests which are specifically tailored to ensure efficacy and consistency for corresponding natural products.
- the invention is further directed to a process for making a dietary supplement comprising a natural composition which has substantial batch-to-batch consistency, said compositional consistency evaluated by a method comprising subjecting a sample of said natural composition to simulated digestion, simulated absorption or both to obtain a preparation of said sample, determining the presence or absence of one or more components in the preparation, and selecting preparations comprising said one or more components.
- the invention also relates to a novel method for evaluating the biological activity of a Ginkgo biloba composition which comprises subjecting a neuronal cell in the presence of said composition to one or more substances or conditions effective to reduce viability of said neuronal cell and measuring the viability of the neuronal cell.
- Another aspect of the invention is a novel method for evaluating the biological activity of a saw palmetto composition which comprises detecting inhibition of the transformation of androgen response receptor to DNA binding form by providing a mixture containing said composition, 5HT, unliganded androgen receptor complexed to HSP90 and androgen response element DNA, and detecting the formation of an androgen receptor-androgen response element DNA complex.
- Fig. 1 depicts the effect of sample preparation method on the macrophage activation capacity of an Echinacea reference product.
- Data represents the mean ⁇ standard deviation of TNF- ⁇ produced from the RAW264.7 macrophage cell-line treated with 20 ⁇ g/ml Echinacea purpurea herb from different sample preparations.
- E-DMSO is the reference product capsule contents dissolved in dimethylsulfoxide (DMSO) solvent;
- E-50% ETOH is the reference product capsule contents dissolved in a 50% Ethanol/water solution;
- E-Digestion is the reference product capsules subjected to a simulated digestion protocol.
- Placebo is placebo soft gel capsules provided by R.P. Scherer NA.
- Fig. 2 depicts the dose-response for macrophage activating capacity of an Echinacea reference product for a preparation subjected to simulated digestion. Data represent the mean of three replicate wells. Standard deviation was less than 5%.
- Fig. 3 depicts the macrophage activating capacity of seven Echinacea raw material samples as compared to two reference standards and a placebo control following simulated digestion. Data represent the mean ⁇ standard deviation for three replicate wells.
- Fig. 4 depicts the macrophage activating capacity (corrected for placebo activity) of eleven Echinacea product samples as compared to a reference standard following simulated digestion. Data represent the mean ⁇ standard deviation for three replicate wells.
- Fig. 5 depicts the results of an assay assessing functional bioavailability for samples of an
- Echinacea reference product and a placebo. Macrophage activating activity was determined before and after simulated absorption by incubation with a Caco-2 cell monolayer. The bars represent the mean ⁇ standard deviation for three replicate assay wells.
- Fig. 6 depicts the lot-to-lot variation for five lots of an Echinacea reference product. Data represent the mean ⁇ standard deviation for three replicate wells.
- the term natural composition is used to refer to a composition believed to be useful as a dietary supplement for maintaining normal structure and function for general well being as defined in DSHEA.
- a natural composition is preferably from a botanical source, and more preferably from an herbal source, but can also be from sources that are not botanical, for example, compositions from animals and other non-botanical living organisms, such as, for example, algae, fungi, bacteria and the like.
- natural compositions include the source itself, as well as selected parts of the source.
- Botanical and herbal compositions can include, for example, stems, flowers, fruits, roots, etc. Leaves of a plant which have been packaged, whole or ground up, for brewing tea, for example, are natural compositions.
- Natural compositions include extracts from the source, for example, ingredients separated from the source by solvent extraction. Solvents can include water, ethanol, methanol, acetone and the like.
- Natural compositions can also include materials from the source which have been modified by other processes such as, for example, enzymatic or chemical modification or digestion. Natural compositions are compositions which comprise all or part of a botanical, herbal, animal or other living organism, and can be unprocessed or processed by physical, enzymatic or chemical means. Natural compositions also include such compositions to which have been added other substances. Other substances are those added for example, to preserve or formulate preparations of the natural compositions, and include for example, preservatives, fillers, binders, lubricants and the like. Natural products are comprised of natural compositions that are in a form ready for use or consumption.
- a natural composition is comprised of a mixture of potentially active and interactive constituents. Such a mixture may contain only two or three constituents that have been identified as being primarily responsible for producing the desired biological effect, but typically contains many more.
- a natural composition when prepared as an extract or mixture of extracts from naturally occurring substances, e.g. substances found in living organisms, a natural composition typically contains many additional constituents, which may be individually present in relatively small and varying quantities, but which in combination may constitute a significant fraction of the total natural composition. These additional secondary ingredients may synergistically contribute to the effectiveness of the primary active ingredients in producing the desired biological effect as well as in suppressing undesired side effects.
- a natural composition differs from co-administered pharmaceutical compositions, inter alia, in that a natural composition is extracted from naturally occurring substances in a manner that results in a composition containing a mixture of both primary and secondary constituents.
- Biofunctionality means the capacity of a composition to bring about an overall change in a condition or characteristic of a living organism.
- biofunctionality means the capacity to affect some aspect of health or well being when consumed as a medicament or dietary supplement.
- overall benefits to health and well being of a natural composition are determined by clinical trials that test effectiveness for the claimed use in treating a health related condition or disease.
- Claimed effects of natural compositions can include, but are not limited to, boosting of the immune system when it is under high stress and enhanced wound healing (Echinacea), maintenance of prostate health (Saw Palmetto), enhanced blood circulation to the extremities and the brain which improves mental capacity (Ginkgo biloba), improvement of liver function and protection against liver damage (Silymari ⁇ ), and as a circulatory stimulant and anti-nauseant (Ginger root).
- Clinical trials typically are not done in a prospective manner due to high cost.
- effects attributed to natural compositions such as maintenance of health and well being and prevention of a disease or an undesired condition cannot be tested by established clinical trials.
- Biological activity of a composition means the capacity of a composition to affect a specific biological characteristic of a cell or group of cells in an ex vivo assay or a biochemical reaction by which it is being tested. Such characteristics include, but are not limited to changes in visible phenotypes, alterations in patterns of gene expression (i.e., alteration in levels of specific mRNA and proteins or polypeptides), changes in secretion of molecules capable of affecting other physiological processes (e.g., cytokines, interleukins, histamine) or changes in sensitivity of test cells to chemicals with known effects (i.e., responsiveness of cells to external stimuli).
- the efficacy of a particular natural composition for achieving the desired biofunctional effect may thus be assessed by testing certain specific biological activities that are associated with that particular biofunctional benefit.
- the ingested natural composition typically contains a mixture of potentially active constituents, and because the range in biological activity may vary considerably depending on the actual in vivo availability (i.e., bioavailability) of each constituent in the natural composition, it is important that assessments of biofunctionality include assays that reliably predict what the biological activity of that natural composition will be in vivo.
- the present invention thus, provides a unique system for reliably predicting the in vivo efficacy of a natural composition on the basis of how it performs in a variety of functional tests once the natural composition has been subjected to simulated digestion and/or abso ⁇ tion.
- the tests are conducted in the form of specifically selected bioassays that demonstrate in vitro biological activities that are closely associated with the in vivo biofunctional benefits ascribed to the natural compositions and often established via clinical trials and subsequent mechanistic studies. Furthermore, these assays have been validated for specificity of response and consistent performance in order to provide reliable results.
- sample preparation methods are employed to achieve the greatest possible correlation with in vivo activity in humans.
- sample preparation may include the use of a simulated digestive model.
- Simulated digestion may include simulated gastric digestion, simulated intestinal digestion, simulated oral digestion, or a combination thereof.
- assay methods of the present invention may employ sample preparation methods which simulate aspects of passage of the natural composition through the digestive tract, extending from the mouth to the colon.
- passage through the digestive tract can have a significant effect on the bioactive components of a given natural composition.
- Activity may be reduced or destroyed by digestive mechanisms.
- those mechanisms may provide for release or activation of inactive precursors from a natural composition.
- Formulations of natural extracts may be devised which protect components which would otherwise be destroyed by digestion in the stomach.
- Simulated digestion thus means a process designed to simulate aspects of the passage of natural compositions through the digestive tract.
- Digestion can be gastric digestion, intestinal digestion or both.
- the present invention typically employs a simulated gastric fluid or a simulated intestinal fluid or a simulated salivary fluid.
- components of the natural composition are subjected to processes which include inactivation by degradation, activation through modification, and selection whereby some components may be actively absorbed whereas others diffuse passively or are not absorbed at all.
- Gastric digestion typically means subjecting material to be tested to a fluid having a pH below about 2.0 and containing digestive enzymes such as pepsin which are active at acidic pH. Gastric digestion can also include agitation which aids in mixing of fluid and materials so as to simulate the mixing that occurs in the stomach. Preferably acidity ranges from about pH 1.0 to about pH 2.0, and is preferably about pH 1.2. Simulated gastric fluids of the present invention can contain gastric enzymes, most preferably pepsin. Most preferably, a gastric fluid is prepared according to the method of United States Pharmacopoeia (USP) volume 23 and contains pepsin. Natural compositions are typically contacted with such gastric fluids at about 25-40°C, preferably at about 37°C. Gastric digestion is performed for an amount of time which is effective to digest the natural composition or extract. Digestion can be form about 2 minutes to about 10 hours. More preferably, digestion is from about 30 minutes to three hours. Most preferably, digestion is for about two hours.
- Digestion can be
- Intestinal digestion involves neutralization of the acidity of a mixture being digested as it moves out of the stomach into the intestine.
- Simulated intestinal fluids of the present invention range between about pH 6.0 and about pH 8.0, preferably between about pH 6.5 and about pH 7.5.
- Such fluids can also comprise digestive enzymes secreted from the pancreas or intestinal lining. Examples of such enzymes are pancreatin, trypsin, chymotrypsin, carboxypeptidase, elastase, lipase and aminopeptidase.
- Intestinal digestion occurs at a neutral pH and preferably involves agitation that aids in mixing of fluid and materials in a manner similar to that which occurs in the intestines.
- Intestinal digestion is from about pH 6.5 to about pH 8.0. More preferably gastric digestion is from pH 7.2 to pH 7.6. Most preferably, gastric digestion is about pH 7.4. Gastric digestion is performed for an amount of time which is effective to digest the natural composition of extract. Digestion can be form about 2 minutes to about 10 hours. More preferably, digestion is from about 30 minutes to three hours. Most preferably, digestion is for about two hours.
- simulated abso ⁇ tion comprises transport of one or more components of a natural composition across a biological membrane. Abso ⁇ tion from the digestive tract occurs through the layer of epithelial cells that form the lining of the digestive tract. For example, amino acids and monosaccharides are absorbed across the epithelial membrane and into capillaries by active transport.
- the epithelial membrane also allows passage of certain substances by diffusion, and can exclude other substances by similar transport mechanisms. Abso ⁇ tion from the digestive tract occurs throughout its length, including intestinal abso ⁇ tion, gastric abso ⁇ tion, sublingual abso ⁇ tion and oral mucosal abso ⁇ tion.
- the present invention can employ a simulated abso ⁇ tion model that simulates transport of components of natural compositions from the environment of the digestive tract across cells which line the digestive tract and into body fluids and tissues.
- cell monolayers are utilized to simulate physiological abso ⁇ tion. Such cell monolayers are established on a permeable surface, such that both surfaces of the monolayer are accessible to a culture medium, the cell monolayer forming a barrier such that the media on both sides of the monolayer are physically separated.
- the cell monolayer performs transport functions, simulating abso ⁇ tion from the digestive tract.
- simulated abso ⁇ tion comprises transport of individual components of a natural composition from the apical side to the basolateral side of the cell monolayer.
- simulated digestion and simulated abso ⁇ tion may be performed concurrently.
- sequential steps will be required where the simulated digestion conditions are incompatible with the simulated abso ⁇ tion conditions. Performing steps concurrently means that the performance of a digestion step and an abso ⁇ tion step overlap to some degree. It is not required that digestion and abso ⁇ tion of a component occur simultaneously.
- Representative cells which may be used to establish a monolayer for the pu ⁇ ose of simulated abso ⁇ tion according to the present invention include Caco-2 cells.
- Other cells which can be used include, but are not limited to HT29 human colon carcinoma cells and Madin-Darby canine kidney (MDCK) cells.
- MDCK Madin-Darby canine kidney
- biological membrane By biological membrane is meant a structure, such as a cell monolayer, which forms a physical barrier across which certain molecules may be transported, depending on the nature of the molecule.
- Alternatives to cell monolayers may of course be utilized to simulate abso ⁇ tion.
- Simulated abso ⁇ tion typically comprise a biological structure capable of active transport and include, but are not limited to, organs of the digestive tract obtained from lab animals and reconstituted organs or membranes created in vitro from cells seeded in an artificial matrix.
- Simulated abso ⁇ tion includes any process which simulates aspects of physiological abso ⁇ tion of components of the natural composition, whether or not modified by digestive processes, from the digestive tract to the body fluids and tissues.
- Simulated abso ⁇ tion may be performed for a preparation over a wide range of time periods, and depends on the nature of the preparation, the biological activity being measured, and the membrane across which the bioactive component is absorbed.
- Simulated abso ⁇ tion can be for periods of time ranging from about 5 minutes to about 48 hours. More preferred embodiments involve time periods of time ranging from 15 minutes to about 4 hours. In the most preferred embodiment, simulated abso ⁇ tion is complete within about 2 hours.
- animal models are used to simulate both digestion and abso ⁇ tion of natural compositions.
- Animals are fed a natural composition and bioavailability is ascertained by testing, for example, serum or blood for the presence or absence of a component or for a specified biological activity. Bioactivity is ascertained in an animal by monitoring physiological or behavioral changes.
- in vitro assays for measuring activity of natural compositions which are useful within the current invention.
- the search for such assays may typically start, for example, with a literature search of clinical studies that have demonstrated a positive clinical effect for the natural product being evaluated.
- the literature may then also be searched for studies that describe the biological mechanism or mechanisms associated with the clinical benefit.
- Particularly useful studies are those that define or suggest a mechanism of action for the specific composition of the natural product that was used in a successful clinical trial.
- the range of functionality for the natural product is then carefully evaluated for each mechanism of action. An appropriate range of functionality may be established using statistical models known in the art. Samples of the natural product may thereafter be selected and evaluated according to the range of functionality which has been established.
- One or more in vitro bioassays may be selected for use with the natural compositions and these bioassays may be selected based on one or more of the following criteria: relatedness of the bioassay to the clinical effect seen in humans; reproducibility; cost-effectiveness; and/or efficiency as a quality assurance tool.
- determining the presence of components within a natural composition include, but are not limited to determinations by physical, chemical or immunological assays or tests. While it is the biological activity that is of interest, it can be the case that a biological response to an active component is manifested over a long period of time, or that an active component accumulates to a useful level in a biological system after multiple doses of the preparation are administered. In these situations, alternative methods for determining active components are particularly useful. In the event that a particular component of a natural composition has been identified, bioavailability of that component following simulated digestion and/or abso ⁇ tion need not be determined by an assay related to its biological activity.
- Any convenient method may be used to determine its presence in a preparation provided by subjecting the natural composition to simulated digestion and/or simulated abso ⁇ tion. Testing for the presence of a component may be performed concurrently with or following the simulated digestion and/or abso ⁇ tion step. Concurrent testing means testing that overlaps a digestion or an abso ⁇ tion step to some degree, but need not occur simultaneously.
- a natural product useful as a dietary supplement comprising a natural composition obtained from a batch of the natural composition, wherein representative samples of the batch are subjected to a method for evaluating biofunctionality.
- Such natural products are distinguishable over prior art natural products in that, inter alia, the natural products of the present invention have greater bio- functional or compositional consistency as compared with prior art natural products.
- Evidence of such greater consistency is established, for example, by collecting a number-of separately packaged samples of the natural products of the invention and comparing the biofunctional consistency of this collection with a number of prior art samples so that a statistical inference can be made.
- the invention is useful for determining biofunctionality of natural compositions and to ensure consistent biofunctionality of natural products, such as dietary supplements.
- This includes, for example, any unprocessed of processed plant material as well as various standardized extracts or combinations of extracts and whole herbal concentrates and is not limited to natural products useful as dietary supplements.
- the assurance of quality and consistency provided by methods of the invention is equally applicable to raw and processed natural compositions, for example those compositions which are raw material for production of dietary supplements.
- the invention includes natural products having substantial batch- to-batch consistency, where the consistency has been evaluated by any of the above methods.
- the assays are repeated with clinically proven products to establish an allowable range of biofunctionality. Once the range of allowable biofunctionality has been established for a product, the assays are useful for testing individual batches. The goal of such testing is to establish that each batch consistently maintains desired characteristics, such as those established in the initial certification stage.
- the analytical methods of the current invention are applicable to a wide variety of natural preparations.
- a particular feature of the present invention is that the assays for testing biological activity are selected on the basis of biological mechanisms which are likely to account for the biofunctionality of the natural preparations. Typically this might mean selecting only two or three mechanisms for which the biological activity is to be tested.
- certifiable products will be within about 50% of a standard composition or activity. More preferably, such products will be within 75% of a standard composition or activity. Most preferably, those products will be within 90% of a standard composition or activity.
- Any product may be tested and certified with any assay, depending only upon the use for which the product is sold. For example, it will be useful to test an herbal product having more than one application according to different methods or standards depending on its intended use. Similarly, it may be desirable to test different products having the same intended use by the same method.
- the range of biological activity can be selected to be that which is known to produce a desired biofunctionality, such that clinical testing may be conducted much more rapidly and cost effectively. Prescreening of materials prior to use in clinical trials allows test boundaries to be established which result in reduced group sizes with a higher degree of response.
- biofunctionality of a natural composition comprising Echinacea or an extract thereof is assessed.
- Laboratory studies have shown that components of Echinacea purpurea possess immunostimulatory activity toward murine and human mononuclear cells (Stimpel et al, 1984; Wagner et al, 1988; Luettig et al, 1989; Roesler et al, 1991; Burger et al, 1997; See et al, 1997).
- Echinacea-ac ⁇ vated macrophages displayed enhanced proliferation, cytokine production, phagocytic activity, and the capacity to kill tumor cells as well as bacterial and fungal pathogens (Stimpel et ⁇ l, 1984; Coeugniet et ⁇ l, 1987; Wagner et ⁇ l., 1988; Leuttig et ⁇ l., 1989).
- the test of biological activity can comprise testing the preparation for immunostimulatory activity.
- Immunostimulatory activity means the capacity to stimulate an activity of an immune system cell.
- Such cells include B cells, T cells, macrophages and the like.
- Such cells of one cell type may be activated by such stimulation, or it can be the case the stimulation of one cell type results in immune cell . interactions which cause activation of other cell types. Activation includes, but is not limited to induction of cell proliferation, secretion of cytokines or other signaling molecules, and secretion of oxygen carrying molecules, such as nitric oxide or peroxide.
- immunostimulatory activity includes the capacity of the preparation to stimulate phagocytic cells such as macrophages.
- a preferred macrophage cell is RAW264.7 and a preferred measure of immunostimulatory activity is production of Tumor Necrosis Factor. Activities of these cell types can also activate other cell types.
- the activity or compositional consistency of an Echinacea composition is determined by first subjecting the natural composition to simulated digestion and/or simulated abso ⁇ tion, followed by biological activity testing of the resulting preparation to determine its effect on lymphocyte activity or phagocytosis.
- the amount of the Echinacea composition that can be assayed for biological activity by the method of Example
- the amount of Echinacea that is subjected to simulated digestion can be from about 10 mg to about 5000 mg. More preferably, the amount is from 100 mg to 2500 mg, Most preferably, the amount is about 750 mg.
- immunostimulatory activity of an Echinacea composition, extract or preparation is determined by monitoring the production of a responsive cytokine. For example, macrophage activation is detected by assessing production of TNF- ⁇ (Leuttig et al., 1989).
- the amount of Echinacea composition used to stimulate production of TNF- ⁇ can be from about 0.1 ⁇ g/ml to about 5 ⁇ g/ml.
- Other responsive species include interleukin-1, interleukin-6, interleukin-8, nitric oxide, reactive oxygen species and arachadonic acid metabolites.
- Macrophages can be monitored for phagocytosis or killing of bacteria.
- macrophage activation and cytokine production supports the development of other immune cell responses, such as natural killer (NK) cell activity and antibody-dependent cellular cytotoxicity (ADCC) (Delfino et al, 1991; See et al, 1997).
- NK natural killer
- ADCC antibody-dependent cellular cytotoxicity
- Macrophage activation and cytokine production support the development and activation of other immune cell types such as NK cells and lymphocytes (See et al, 1997; Delfino et al, 1991).
- Echinacea-de ⁇ ved polysaccharides do not induce substantial proliferation of isolated lymphocytes (Luettig et al. , 1989) but lymphocyte proliferation and NK cell activation does occur in vitro from stimulation of peripheral blood mononuclear cells (macrophages, NK cells, and lymphocytes; PBMCs) in vitro (See et al, 1997) and in vivo (Coeugniet et al, 1987).
- PBMCs peripheral blood mononuclear cells
- Echinacea compositions which have been prepared by methods of the invention and viable cell number are assessed. Final concentrations of
- Echinacea preparations can be used in concentrations from about 0.1 ⁇ g/ml to about 5 ⁇ g/ml. more preferably from 0.5 ⁇ g/ml to about 2.5 ⁇ g/ml and most preferably 1 ⁇ g/ml.
- a preferred and easily performed method for assessing viable cell numbers consists of monitoring conversion of the metabolic dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT).
- MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
- Other metabolic dyes are well know and can also be used.
- Methods for assessing viability also include, but are not limited to, measuring uptake of labelled nucleotides or amino acids (e.g., 3 H-thymidine) and measuring ATP levels by bioluminescence (e.g., by ViaLight kit, LumiTech Ltd., Nottingham, U.K.).
- Methods for assessing macrophage stimulation are not limited to detection of TNF- ⁇ and evaluation of cell proliferation.
- Other methods include, but are not limited to detection of synthesis of prostaglandins, other cytokines like IL-l ⁇ , IL-l ⁇ , nitric oxide, and oxygen radicals like superoxide and peroxide. It is well known in the art to measure cytokines and biological activities produced by cultured cells. For example, ELISA kits and cell proliferation assay kits to measure cytokines are readily available.
- biofunctionality of a natural composition comprising Ginkgo biloba or an extract thereof is tested.
- Ginkgo biloba extracts GBE
- Recent studies have described the beneficial effects of Ginkgo biloba extracts (GBE) on patients with different types of dementias, mood changes, disturbances in cognitive functions associated with aging and senility, poor concentration and memory, confusion, depression and anxiety (Warot et al. , 1991 ;
- GBE typically comprises four different phytochemicals which include flavone glycosides, te ⁇ enoids, proanthocyanidins, and organic acids. Flavonoids have been shown to scavenge free radicals and act as antioxidants. Free radical oxidation reactions are believed to be part of the aging process and are presumed to be major contributors to mental decline. Oxidative stress is implemented in the pathogenesis of several neurodegenerative disorders.
- Ginkgo flavonoids have been shown to protect cells from lipid peroxidation and cell death (Joyeux et al, 1995; Robak et al, 1988), protect neurons from necrosis and apoptosis induced by oxidative stress (Oyama et al, 1996; Ni et al, 1996), and reduce oxidative metabolism in both resting and Ca 2+ loaded neurons (Oyama et al, 1994).
- activity of a Ginkgo biloba composition is tested by first subjecting the natural composition to simulated digestion and/or simulated abso ⁇ tion, followed by biological activity testing of the resulting preparation to determine its ability to scavenge free radicals.
- the amount of Ginkgo biloba which is digested according to the method of example one can be from about 5 mg to about 1000 mg.
- the amount is from 25 mg to 500 mg, Most preferably, the amount is about 180 mg.
- free radical scavenging is observed by monitoring the decoloration of a free radical reagent. It will be apparent to one of average skill in the art that many other oxidants and methods of testing for their presence and inactivation can also be used to test compositions of Ginkgo biloba following simulated digestion and/or abso ⁇ tion.
- the ability to scavenge free radicals is tested by mixing Ginkgo biloba compositions in a solution containing free radicals.
- Preferred free radicals are detectable for example by absorbance, and scavenging is detected by a change in absorbance of the solution.
- the amount of Ginkgo biloba required can vary according to the free radical to be quenched, the Ginkgo concentration can be from about 1 ⁇ g/ml to about 500 ⁇ g/ml, more preferably
- biofunctionality of a natural composition comprising Ginkgo biloba or an extract thereof is tested for its ability to inhibit platelet activating factor (PAF).
- the te ⁇ enoid fraction of Ginkgo contains ginkgolides of which Ginkgolide B is a potent inhibitor of platelet activating factor (PAF) (Nunez et al, 1986; Smith et al, 1996).
- PAF platelet activating factor
- PAF is also known to activate cells involved in inflammation (Braquet et al. , 1987), regulate cellular immune responses (Prescott et al. , 1990), alter blood rheology and vascular permeability (Kinn et al, 1998).
- PAF is involved in shock responses and post ischemic events (Baker, 1995), reduces cerebral blood flow (Kinn et al, 1998), modulates synaptic activity (Bazan et al. , 1995; Yue et al. , 1994), plays an important role in brain development and is implicated in certain CNS disorders (Hattori, 1994; Smith et al, 1996).
- Ginkgolide B has been shown to inhibit most of these functions of PAF in experimental models.
- inhibition of platelet activation is assessed by determining the ability of a composition of Ginkgo biloba, following simulated digestion and/or abso ⁇ tion, to inhibit platelet aggregation.
- Platelet activation and inhibition thereof can be measured in an aggregometer.
- Methods for making platelet rich plasma are well known in the art.
- a mixture is provided containing platelets, an agonist (platelet activating factor) which induces platelet activation and a Ginkgo biloba composition.
- the agonist can be Racemic-PAF.
- a preferred agonist is L-PAF.
- the concentration of the agonist can be from about 0.001 ⁇ M to about 0.1 ⁇ M, more preferably from 0.003 ⁇ M to 0.05 ⁇ M and is most preferably about 0.006 ⁇ M.
- a range of concentration can be chosen for the Ginkgo biloba composition being tested.
- a standard Ginkgolide may be employed and inhibition of platelet activation compared to that of the Ginkgo biloba compositions and preparations.
- the concentration of Ginkgolide standard can be from about 0.05 ⁇ M to about 10 ⁇ M, and is more preferably from 0.25 ⁇ M to about 2.5 ⁇ M, and is most preferably 1.0 ⁇ M.
- the biological activity of Ginkgo biloba which protects neuronal cells from toxicity associated with certain substances and growth conditions is assayed.
- assays which mimic individual steps of neurodegenerative processes and which can be used to assess biological activity of Ginkgo biloba compositions.
- Substances and conditions known to be toxic to neuronal cells include high levels of an excitatory amino acid (glutamate), and amyloid- ⁇ peptide (Janssens et al, 1995; Behl et al, 1994). Serum starvation also promotes apoptotic death of cultured neuronal cells.
- neuronal cells are cultured under known toxic conditions. Neuronal cells are subjected to the aforementioned conditions or combinations thereof in the presence and absence of Ginkgo biloba. The ability of compositions of Ginkgo biloba to reduce or prevent toxicity is determined by assessing cell viability.
- Insults against which Ginkgo biloba has demonstrated protection include the following: (1) induction of apoptosis by serum starvation; (2) glutamate induced excitotoxicity; (3) cytotoxicity of conditions mimicking ischemia; (4) cytotoxicity of unpolymerized amyloid- ⁇ peptide; (5) cytotoxicity of fibrillar amyloid- ⁇ peptide; (6) induction of apoptosis in the presence of high concentrations of glutamate; (7) induction of apoptosis in the presence of amyloid- ⁇ peptide; (8) cytotoxicity of conditions mimicking ischemia followed by excitotoxic insult; (9) cytotoxicity of amyloid- ⁇ peptide in the presence of Fe ions; (10) cytotoxicity of amyloid- ⁇ peptide in the presence of high concentrations of glutamate; (11) induction of apoptosis in the presence of amyloid- ⁇ peptide and high concentrations of glutamate.
- a mixture is provided containing neuronal cells, a cytotoxic substance in an amount sufficient to reduce viability and a Ginkgo biloba preparation.
- the cytotoxic substance can be glutamate which is present in a concentration from about 1 mM to about 50 mM, and is more preferably from 2.5 mM to about 20 mM, and is most preferably 10 mM.
- the cytotoxic substance can be amyloid- ⁇ peptide and be present from about 0.05 ⁇ M to about 10 ⁇ M, more preferably from 0.2 ⁇ M to about 1.0 ⁇ M, and most preferably 0.5 ⁇ M. Extracts and compositions are tested to determine the extent to which they inhibit cytotoxicity.
- the invention is also useful for assessing the biofunctionality of a composition comprising St. John's Wort or an extract thereof.
- St. John's Wort has been demonstrated to be effective against mild to moderate depression (Chatterjee et al. , 1998a; Laakmann et al. , 1998) with few side effects (Vorbach et al, 1997; Linde et al, 1996). Although the mode of action is not known, in vitro bioassays indicate that inhibition of serotonin re-uptake and dopamine re-uptake are the predominant specific activities (Muller et al, 1997). Serotonin re-uptake inhibition is a well established mode of action of many synthetic anti-depressants.
- Embodiments of the invention are not limited to assays for serotonin re-uptake inhibition, and can include, for example, assays for inhibition of monoamine oxidase (Bladt et al, 1994; Thiede et al, 1994) or inhibition of GABA binding to the GABA receptor (Baureithel et al, 1997; Cott, 1997).
- a composition comprising St. John's Wort is subjected to simulated digestion and/or simulated abso ⁇ tion, and the resulting preparation is tested for serotonin re-uptake inhibition activity.
- the test of biological activity can comprise providing a mixture containing the St. John's Wort preparation, a synaptosomal preparation and a neurotransmitter selected from the group consisting of dopamine and serotonin, and detecting uptake of the neurotransmitter by the synaptosomal preparation.
- Synaptosomes can be prepared, for example, from brain tissue by homogenization in ice-cold 0.32M sucrose solution as described elsewhere herein.
- brain tissue volume can be approximated by weighing and the amount of sucrose solution added can be about one volume to about 50 volumes, and is more preferably from about 5 volumes to 15 volumes and most preferably is about 9 volumes.
- the amount of synaptosome preparation use in the assay mixture can be from about 5 ⁇ l to about 1 ml, and is more preferably 20 ⁇ l to 250 ⁇ l and most preferably 50 ⁇ l.
- the neurotransmitter can be dopamine or serotonin, and can be present in the extract at a concentration from about 2 nM to about 500 nM, more preferably from 5 nM to 100 nM, and most preferably about 50 nM. The amount of the St.
- John's Wort composition that can be assayed for biological activity by the method of Example 1 can vary significantly.
- the amount of St. Johns Wort that is subjected to simulated digestion can be from about 10 mg to about 5000 mg. More preferably, the amount is from 100 mg to 2500 mg, Most preferably, the amount is about 900 mg.
- a convenient way to measure uptake use a radiolabeled neurotransmitter. Examples of convenient labeled neurotransmitters ate 14 C-serotonin, 3 H-serotonin, 3 H-dopamine.
- the re-uptake measurement period can be from about 15 seconds to about 15 minutes, and is more preferably 1 to 10 minutes and is most preferably 5 minutes.
- the present invention is useful for assessing the activity of a composition comprising saw palmetto or an extract thereof.
- Saw palmetto as a dietary supplement most commonly consists of an extract derived from the fruit of the American Dwarf Palm Tree (Serenoa repens).
- saw palmetto is a well accepted and clinically studied remedy for symptoms associated with benign prostate hype ⁇ lasia (BPH). While the exact etiology of BPH is not fully elucidated, the metabolism and action of androgenic steroids and conversion of testosterone to dihydrotestosterone (5HT) by 5 ⁇ -reductase appears to be strongly associated with the development of BPH (Strauch et al, 1994; Isaacs et al, 1983).
- inflammatory mediators such as prostaglandins and leukotrienes produced by infiltrating leukocytes as well as localized growth factors such as basic fibroblast growth factor (bFGF) (Robinnette, 1988;
- saw palmetto has been shown to block androgen-mediated prostate growth in castrated animals and pharmacokinetic labeling experiments have shown that major components of saw palmetto, (e.g., linoleic acid, oleic acid) distribute to the prostate (Chevalier et al, 1997; Paubert-Braquet et al, 1996).
- compositions comprising saw palmetto and extracts thereof are assessed for their capacity to inhibit 5 ⁇ -reductase.
- biological activity is assessed by measuring inhibition of metabolism of one or more 5 ⁇ -reductase substrates (e.g., testosterone and/or progesterone) in a mixture which comprises 5 ⁇ -reductase from rat liver microsomes, NADPH and the 5 ⁇ -reductase substrate(s) and the saw palmetto composition.
- 5 ⁇ -reductase substrates e.g., testosterone and/or progesterone
- the saw palmetto composition is present at a concentration between about 5 ⁇ g/ml and about 500 ⁇ g/ml, more preferably between 10 ⁇ g/ml and 100 ⁇ g/ml, and most preferably at about 50 ⁇ g/ml.
- the amount of the microsome preparation present in the assay can be from about 2 ⁇ l to about 200 ⁇ l, more preferably 5 ⁇ l to 50 ⁇ l, and most preferably 20 ⁇ l.
- 5 ⁇ -reductase substrates are present at from about 5 ⁇ g/ml to about 500 ⁇ g/ml, and more preferably 20 ⁇ g/ml to 200 ⁇ g/ml.
- the testosterone concentration is 25 ⁇ g/ml and the progesterone concentration is 20 ⁇ g/ml.
- the reaction is started by the addition of NADPH to a final concentration of about 20 ⁇ g/ml to about 2 mg/ml, more , preferably 50 ⁇ g/ml to 1 mg/ml, and most preferably 490 ⁇ g/ml.
- the incubation is between about 30°C and about 40°C, more preferably between 35 °C and 39°C, and most preferably at about 37 °C for a period of time from about 5 minutes to about 2 hours, more preferably 30 minutes to 90 minutes and most preferably for about 1 hour.
- a likely mode of action is inhibition by SPE of the transformation of androgen receptor to the DNA binding form. It has been discovered that SPE inhibits the transformation of aryl hydrocarbon receptor to the DNA binding form. Based on the present discovery that SPE inhibits transformation of aryl hydrocarbon receptor and a critical review of the literature, it is believed herein that SPE is a noncompetitive, non-specific inhibitor of HSP90-bound hormone receptor transformation. By use of the term "non-specific,” it is meant that SPE has the capacity to inhibit transformation to DNA binding form of aryl hydrocarbon receptor, androgen receptor, and perhaps other receptor proteins which can undergo a like transformation.
- aryl hydrocarbon receptor is not part of the androgen or estrogen receptor family, nor directly involved in hormone signal transduction, all these receptors use similar mechanisms to maintain unliganded competence and for activation to the liganded DNA-binding form, and all have corresponding defined DNA response elements to which they bind.
- An anti-estrogen effect has been shown for SPE which prevents the appearance of nuclear estrogen receptor (Di Silverio et al, 1992; Bombardelli and Morazzoni, 1997).
- IC 50 for the tested SPE is found to be 20 ⁇ g/ml. This is in the same range found for enzyme inhibition activity for SPE.
- androgen response element DNA is diluted in cytosol or nuclear extract which is the source of unliganded androgen receptor bound to HSP90, to a concentration between about 0.01 nM and about 1000 nM, more preferably between 0.1 nM and 10 nM, most preferably about 1.0 nM. Androgen response element may be biotinylated depending upon the detection method employed. Microsomes are prepared as above. The amount used in an assay can vary between about 30 ⁇ l and about 3000 ⁇ l, more preferably between 100 ⁇ l and 1000 ⁇ l, and is most preferably about 500 ⁇ l.
- Testosterone is present between about 0.5 ⁇ g/ml and 200 ⁇ g/ml, more preferably between 1 ⁇ g/ml and 100 ⁇ g/ml, and most preferably is about 50 ⁇ g/ml.
- Saw palmetto material and NADPH are then added to the mixture.
- Concentrations for each may be about 1.0 ⁇ g/ml to about 1000 ⁇ g/ml, more preferably 10.0 ⁇ g/ml to 200 ⁇ g/ml, and most preferably about 100 ⁇ g/ml.
- Similar conditions may be employed for assays based on aryl-hydrocarbon receptor and response element. Methods for detecting the formation of complexes such as those between androgen response element DNA and androgen receptor are well known in the art. For example, they can be immunologically based, relying on binding of an element to a solid support.
- an embodiment of the invention which tests for biological activity of a saw palmetto composition or extract comprises providing a mixture containing the saw palmetto preparation, 5 ⁇ -reductase, cofactor NADPH, testosterone, unliganded androgen receptor complexed with HSP90 and androgen response element DNA, and detecting the formation of an androgen receptor-androgen response element complex.
- the test comprises providing a mixture containing the saw palmetto preparation, unliganded aryl hydrocarbon receptor complexed with HSP90 and aryl hydrocarbon response element DNA, and detecting the formation of an aryl hydrocarbon receptor-aryl hydrocarbon response element DNA complex.
- a novel assay capable of monitoring anti- androgenic inhibition by SPE of the transformation of androgen receptor. This assay provides capability to simultaneously measure the contribution to anti-androgenic activity from inhibition of 5HT formation by 5 ⁇ -reductase.
- a particularly useful aspect of this novel assays is that it provides a measurement of biological activity of saw palmetto extracts and commercial products as well as saw palmetto- containing compositions prepared by simulated digestion and abso ⁇ tion methods of the current invention.
- a frequent occurrence with BPH is a hormone-induced chronic inflammation that results from infiltration of inflammatory macrophages and neutrophils into the prostate (Theyer et al, 1992).
- Production of prostaglandins such as prostaglandin E 2 (PGE2) and leukotrienes (leukotriene B4, LTB4) are known inflammatory mediators produced by these cells (Robinette, 1988; Theyer et al, 1992).
- PGE2 prostaglandin E 2
- leukotriene B4, LTB4 leukotriene B4, LTB4
- embodiments of the invention include those which assess the anti-inflammatory activity of a saw palmetto composition or extract.
- Previous studies implicating infiltration of inflammatory immune cells suggest the central role of secreted mediators of inflammation (e.g., cyclooxygenase and macrophage derived cytokines) in diseases which are ameliorated by saw palmetto.
- pharmacokinetic data indicating in vivo bioavailability at the target site exists and supports an anti-inflammatory mechanism of action for saw palmetto (Chaudry et al, 1994; Plosker et al, 1996).
- macrophage activation can be measured in a variety of ways.
- levels of biological activity of a saw palmetto composition or extract is assessed by measuring inhibition of production of prostaglandin E 2 (PGE 2 ).
- compositions and extracts of Panax ginseng are evaluated for biological activity and compositional consistency.
- Panax ginseng has been used in traditional Chinese medicine for approximately 2000 years to enhance stamina and improve responses to fatigue and stress. Although mechanisms of action remain unclear, effects have been observed which involve the central nervous system (memory, learning and behavior;
- Ginseng is thought to act on the hypothalamus, causing release of corticotropin, which in turn acts on the pituitary to release ACTH, which acts on the adrenals to release corticosteroids.
- corticotrosteroids and adrenocorticotropic hormone act on the brain and body to provoke stress adaptation (Fulder, 1980; Fulder, 1981).
- Ginseng exhibits a potentially synergistic effect by also binding and activating glucocorticoid receptors, mineralcorticoid receptors and progesterone receptor (Pearce et al.1982; Lee et al.1997).
- ginseng Activities attributed to ginseng are believed to be due to ginsenosides, which have been shown to bind and activate glucocorticoid receptors as well as bind to mineralcorticoid and progesterone receptors.
- the most commonly studied activities of glucocorticoids involve the modulation of nitric oxide synthase isoenzymes, especially the inhibition of inducible nitric oxide synthase (iNOS) (Di Rosa et al.1990; Park et al.1996).
- iNOS inducible nitric oxide synthase
- Glucocorticoid receptor-mediated inhibition of iNOS expression under stress/inflammatory conditions has beneficial effects on blood flow, maintenance of cardiac muscle contractility, and beneficial immunological activities, permitting expansion of T and B lymphocytes and up-regulation of cytokine receptors on immune cells (Radomski et al.1990; Hawrylowicz et al.1994).
- Embodiments of the invention enable the evaluation of ginseng extracts and compositions for biological activities which stimulate corticosteroid induction and inhibit nitric oxide production.
- a ginseng extract is administered to an animal and levels of corticosterone are measured in blood plasma.
- ginseng extracts are tested for their ability to inhibit nitric oxide production in cultured macrophage cells activated with IFN- ⁇
- Biofunctionality Determination of the benefit provided by a natural composition after consumption is improved by testing the material in bioassay(s) following a simulated digestion and/or abso ⁇ tion process. Simulation of these physiological processes adds stringency to the assessment of biofunctionality, the result being a better indication of potential in vivo activity. Because herbs and natural extracts are complex materials, digestion enhances or reduces abso ⁇ tion and subsequent biological activity.
- a final formulation composition (tablet, capsule, soft gelatin capsule, etc.) was added to 15 ml of simulated gastric fluid prepared following the method of USP volume 23.
- the gastric fluid had a pH of approximately 1.2 and contained the gastric enzyme pepsin, thus simulating the digestive environment of the stomach.
- the contents were then shaken at 250 RPM at 37°C for 2 hours for dissolution of the test material.
- the pH of the resulting mixture was then adjusted to approximately 7.4 by the addition of 0.5 ml of a 2.2N solution of sodium hydroxide and the addition of an equal volume (15.5 ml) of 2X concentrate of simulated intestinal fluid containing 2X pancreatin.
- the flask was shaken at 250 RPM at 37°C for 2 hours. This resulting solution was an approximation of physiologic intestinal fluid containing pancreatic enzymes that the test material would be exposed to upon oral consumption.
- the material was then flash frozen and stored at -80 °C for further testing.
- Caco-2 cells purchased from the American Type Culture Collection (ATCC, Rockville, MD) were maintained in T-75 culture flasks with Dulbecco's Modified Eagle's Media (DMEM, Gibco, Grand Island, NY) containing 10% fetal bovine serum (Gemini Bio-Products, Calabasas, CA) and 100 units/ml penicillin - streptomycin solution (Sigma, St. Louis, MO).
- DMEM Dulbecco's Modified Eagle's Media
- Gibco Gibco, Grand Island, NY
- penicillin - streptomycin solution Sigma, St. Louis, MO
- Caco-2 cells A convenient alternative to Caco-2 cells is the BIOCOAT® Intestinal Epithelium Environment system (Becton Dickenson, Franklin Lakes, NJ.
- the kit can provide a confluent layer of cells in about 3 days.
- Test material may either be dissolved in DMSO or 50% ethanol, or may consist of an aliquot from a simulated digestion protocol (see above). Samples from the digestion protocol were diluted or incubated at 50 °C to heat inactivate pancreatic enzymes. This step is used to remove pancreatic enzymes which may be toxic to cells and thus could ruin the integrity of the Caco-2 monolayer. The test sample was then added to the apical side of the cells and then incubated at 37°C. Incubation temperature can be lower.
- the BIOCOAT system allows assays to be performed at room temperature and can with incubation times from about 10 minutes to about 2 hours or longer.
- Aliqouts for biofunctional testing were taken from the apical and basolateral compartments at 30, 60 and 90 minutes following administration of the test material.
- bio-functional testing is performed using cell lines capable of growing in the same culture media as the Caco-2 monolayer
- the procedure can performed using cell culture wells containing the target test cell line on the basolateral side of the monolayer. The transwells and the supported Caco-2 cell monolayer are removed once abso ⁇ tion is complete.
- Table 1 depicts pH after completion of simulated digestion of various botanical materials for experiments performed on three different days.
- Table 2 biological activity was assessed for two different botanicals using material from at least three different digestions of the same lot of starting material. Activity was assessed using the Echinacea Macrophage Activation Assay (Example 2) or the Ginkgo biloba free radical scavenging assay (Example 3).
- the data shown in the Tables 1 and 2 show a relative standard deviation (CV), a description of variability, of less than 10% for simulated digestion and functional biological activity.
- Echinacea extracts and compositions prepared using the simulated digestion and abso ⁇ tion models described above were evaluated in vitro based on their ability to stimulate TNF- ⁇ production by macrophages and to stimulate cell proliferation of PBMCs.
- Fig. 1 shows a comparison of TNF- ⁇ production by macrophages which was induced by a placebo and by the various preparations of the powdered Echinacea product.
- the Echinacea product prepared by simulated digestion retained a significant amount of TNF- ⁇ stimulating activity, whereas the products prepared by either of the common extraction methods demonstrated no activity above that of the placebo.
- the macrophage activating capacity was dose dependent, indicating specificity.
- Echinacea raw materials and products A variety of Echinacea raw materials and products were tested for macrophage activating activity after simulated digestion. As shown in Fig. 3, when compared to a reference material and a placebo control, only two of seven raw material batches demonstrated a significant capacity to induce macrophage TNF- ⁇ production. A comparison of samples of available Echinacea products is depicted in Fig. 4. Of eleven tested products, only three demonstrated a capacity to activate macrophages which was comparable to the reference.
- PBMCs Peripheral blood mononuclear cells
- Echinacea sample prepared by simulated gastric and intestinal digestion.
- a vial of cells (about 5 x 10 7 cells) was thawed and suspended in Lymphocyte Growth Medium (LGM-3, Clonetics) prewarmed to 37 °C.
- LGM-3 Lymphocyte Growth Medium
- One hundred ⁇ l of cell suspension was dispensed into each well of a 96-well microtiter tissue culture plate.
- the test samples, digested placebo capsules, Echinacea reference material, and Concanavalin A (Con A, positive control) were prepared to 10X concentrations in LGM-3 media and 10 ⁇ l of respective test material was added to the wells.
- the cells were incubated for approximately 72 hours and evaluated for proliferation/viability via conversion of the metabolic dye, MTT, using a Cell TiterTM Proliferation Assay Kit (Promega, Madison, WI). 1 ml of supplied MTT dye solution was added to 5 ml of LGM-3 solution and 50 ⁇ l of MTT/LGM-3 media was added to each well. After incubation at 37°C for 2 hours, 100 ⁇ l of stop/solubilization solution was added and the optical density at 570 nm was determined using a BioTEK Instruments ELISA plate reader. Table 3 shows the dose response relationship between Echinacea concentration and cell proliferation. Table 4 shows the dose response relationship between the positive control compound, Con A, and cell proliferation.
- Echinacea or Con A Values for each concentration of Echinacea or Con A represent means of 8 wells. Statistical significance (P) was calculated using the one-tailed student's T-test versus placebo capsule response. Cell proliferation peaked at a concentration of digested Echinacea which was about 1 ⁇ g/ml. Con A also produced a dose-dependent response and 1 ⁇ g/ml produced a high level of stimulation, and was thus chosen as a dose for following experiments.
- Table 5 shows the interassay variability and lot-to-lot reproducibility of the Echinacea standard for the PBMC proliferation assay using cells from a single donor.
- Table 6 demonstrates a significant proliferative response from PBMCs of three different donors. For each set of assays, eight replicate wells were assayed on three or more days using 1 ⁇ g/ml digested Echinacea or Con A. All Echinacea lots and Con A were statistically different than placebo (PO.01).
- Example 3 In Vitro Assays for Biological Activity of Ginkgo biloba Preparations. Assays developed for Ginkgo biloba assessed the direct antioxidant activity of the herbal product, the ability to inhibit binding of platelet activating factor to its receptor and the ability of Ginkgo biloba to block neuronal cell death following either a mitochondrial insult or exposure to amyloid- ⁇ peptide.
- Table 7 shows the mean percentage of scavenged free radicals for different concentrations of Ginkgo biloba compositions.
- the compositions were a standardized undigested Ginkgo , extract, the same standardized extract subjected to simulated digestion and three different Ginkgo biloba products also subjected to simulated digestion. The results indicated that the free radical scavenging activity of Ginkgo biloba was affected by digestion.
- PRP Platelet poor plasma
- Optical platelet aggregometry was performed using a Chrono-Log platelet aggregometer at 37°C with stirring at 850 rpm. For each test, 450 ⁇ l PRP was added to the aggregation cuvette with a Teflon® stir bar, and the cuvette was placed in the measuring cell of the aggregometer. A cuvette containing 450 ⁇ l of autologous PPP, a stir bar, and 50 ⁇ l of 0.15 M NaCl (prewarmed to 37°C) was placed in the reference cell position of the aggregometer. The baseline was set using the set baseline mode. The maximal pen deflection (distance in mm) from the baseline for PPP relative to PRP is recorded on the chart.
- the PRP was prewarmed for 1 minute at 37°C with stirring followed by addition of 5 ⁇ l of inhibitor or extract in DMSO or other vehicle using a Hamilton micro syringe and allowed to react with platelets for 1 minute followed by addition of 5 ⁇ l of platelet agonist.
- the aggregation response profile was recorded for 3 minutes after agonist or control additions.
- the preferred agonist is L-alpha-phosphatidylcholine,beta-acetyl-gamma-O-hexadecyl (L-PAF, Sigma) which has been found to have significantly higher activity than DL-alpha-phosphatidylcholine,beta-acetyl-gamma-O-hexadecyl (racemic PAF).
- Platelet aggregation was determined as follows. Light transmission of the PRP solution after addition of a saturating level of PAF represented 100% platelet aggregation. Light transmission of a control solution of PPP after the addition of vehicle (e.g., DMSO) represented 0% platelet aggregation. Light transmission values were corrected for the effects of other components of the solution by performing parallel measurements of light transmission of a similarly treated PPP solution. To determine a linear range for the assay, test reactions were performed which contained different concentrations of L-PAF. To measure inhibition of Gingko biloba extracts, a concentration of L-PAF was chosen which was in a linear range of the assay.
- vehicle e.g., DMSO
- Table 9 shows a dose-response analysis of the inhibition of L-PAF induced platelet aggregation by Ginkgolide B.
- Dose response curves were established at four different PAF concentrations representing different levels of platelet activation (% of maximal response).
- the IC 50 for Ginkgolide B was dependent on the extent of platelet activation.
- the data obtained for the linear regression coefficients showed that there was a linear response (based upon correlation coefficient, r) of platelet aggregation inhibition at and above 0.02 ⁇ M PAF. Therefore, this PAF concentration (0.02 ⁇ M) was used in further experiments to obtain the highest sensitivity with a linear response.
- IC 50 values for Ginkgo biloba reference material and Ginkgolide B standard were determined for three independent platelet preparations at the selected PAF concentration. A linear relationship between Ginkgo biloba concentration and platelet aggregation inhibition is found in the tested range (r>0.99; data not shown). Moreover the activity of Ginkgo biloba relative to Ginkgolide B (Ginkgolide B lC 50 /Ginkgo biloba IC 50 ) is independent of platelet preparations at the selected PAF concentration.
- relative activity (Ginko biloba test material ⁇ C 5Q /Ginkgo biloba standard IC 50 ) can used to compare functional inhibitory activity on platelet aggregation for Ginkgo biloba preparations.
- Table 12 shows reproducibility achievable among different preparations of one lot and among different lots of the reference material.
- the minimum activity required for product certification depends on the accuracy and precision of the assay used to determine activity, reproducibility of data from the different preparations of the same reference material and variability between different lots of reference materials.
- the standard deviation shown by the assay in determining relative activity for the same reference material is low (2.7%, Table 11).
- variability due to sample preparation within the same lot and variability among lots is also low.
- Neuronal precursor cells either human or non-human
- Conditions were optimized to demonstrate a protective effect of the reference Ginkgo biloba material. Metabolic activity of treated cells in the presence and absence of the herbal reference material was compared to that of untreated cells.
- Amyloid ⁇ -peptide 25-35 was obtained from Bachem Bioscience Inc. Peptide was dissolved in DMSO at 1 mM final concentration and aliquoted under N 2 atmosphere and kept at -30°C. A fresh aliquot was used in each experiment and diluted to the required concentration into culture medium just before use. Glutamate was purchased from Sigma (St.
- the PC- 12 precursor neuronal cell line (rat adrenal pheochromocytoma) was obtained from ATCC (Rockville, MD) and cultured in DMEM medium containing 10 % fetal bovine serum
- FBS heat inactivated horse serum
- Heat inactivated horse serum was from Sigma (St. Louis,MO).
- Other tissue culture reagents were from Gibco. Cells were grown on collagen coated tissue culture surfaces. The fibrillar form of collagen (Cell Prime Collagen, Cohesion Technologies, Inc., Palo Alto, CA) was prepared according to the manufacturer's instruction and used to coat the tissue culture flasks and 96 wells plates in a form of a thin layer. Cells were dislodged from the plate by trituration.
- Cell clusters were broken up by vigorous pipetting and the cell suspension was filtered through a cell strainer to obtain even cell number and seeded at a cell density of 10 4 /well 24 hours before experiments.
- Cells were pretreated with the Ginkgo biloba reference material that was dissolved in DMSO at 10 mg/ml concentration and diluted into culture medium at the required concentration just before use.
- Table 13 shows cytotoxicity to PC 12 cells of glutamate, amyloid- ⁇ peptide and a combination of both. The most dramatic decline in viability (% surviving cells) occurs from 48 to 72 hours. By 96 hours, cell numbers have started to increase as remaining viable cells replicate.
- Tables 13 shows the dose-response relationship of a Ginkgo biloba reference material added to the culture and the resulting reduction in cellular toxicity of glutamate, amyloid- ⁇ peptide and a combination of both.
- Cell viability was determined 48 hours post-treatment (Table 14) and 72 hours post-treatment (Table 15). In all cases, addition of the reference material resulted in increased viability.
- the ability of the Ginko biloba reference material to protect serum starved cells challenged with amyloid- ⁇ peptide was also investigated.
- Table 16 shows the further reduction in viability to cells cultured with two concentrations of amyloid- ⁇ peptide which results from serum starvation.
- the protective effect of the Ginkgo biloba reference material extends to serum starved cells. This assay is used to test Ginkgo biloba preparations resulting from simulated digestion and/or abso ⁇ tion for neuroprotective effectiveness.
- St. John's Wort Hypericum perforatum extracts and compositions were prepared using a simulated digestion model as described above. To reduce degradation of active constituents, incubations for gastric digestion and intestinal digestion were each conducted for one hour. The resulting preparations are evaluated in vitro for ability to inhibit 3 H-dopamine and 3 H-5-HT (serotonin) re-uptake in rat cortex synaptosomes.
- the assays exemplified are relevant to the mode of action of anti-depressants in general, and to the suspected mechanism of action of St. John's Wort formulations.
- Rat brain synaptosome Preparation Rat brain synaptosomes were prepared from striata for 3 H-dopamine uptake or from whole brain minus cerebellum for 3 H-5-HT uptake according to the method of Gray and Whittaker (1962). Briefly, male Sprague-Dawley rats were decapitated and the brains were rapidly removed. Either striata or whole brain minus cerebellum was weighed and homogenized in 9 volumes of ice-cold 0.32 M sucrose solution using a Potter-Elvejhem homogenizer. The homogenate was centrifuged at 1,000 g at 0-4 °C for 10 minutes. The supernatant was decanted and used for uptake experiments.
- incubation medium of the following composition: 109 mM NaCl, 3.55 mM KC1, 2.4 mM CaCl 2 , 0.61 mM MgSO 4 , 1.1 mM KH 2 PO 4 , 25 mM NaHCO 3 , 5.4 mM glucose, 0.025 mM nialamide, pH 7.4 (this medium is gassed with 95% O 2 , 5% CO 2 , 30 minutes prior to use) with either 20 nM 3 H-dopamine or 20 nM 3 H-5-HT. An incubation period of 5 minutes was employed.
- Specific uptake of 3 H-dopamine and 3 H-5-HT is defined as the difference between the total uptake at 37°C and uptake at 4°C.
- GBR 12783 and imipramine were used as reference compounds for the 3 H-dopamine and 3 H-5-HT uptake assays, respectively.
- Stock solutions (10 mg/mL) prepared in DMSO were centrifuged at 17,000 g for 10 minutes and the supematants were used in the assays. Samples were stored at 4°C for a maximum of about 5 days in amber colored bottles. Further dilutions were made in incubation medium.
- Table 17 shows the inhibition of serotonin re-uptake for a reference St. John's Wort composition, as well as for a composition which has been subjected to gastric digestion alone or to gastric and intestinal digestion.
- the data represents the mean radioactivity counts of four replicate readings per sample and student's T-test statistical analysis (P) for significant activity versus the matched control. All St. John's Wort samples demonstrated significant serotonin re-uptake inhibition.
- inhibition was noticeably reduced where the St, John's Wort product had been subjected to simulated gastric digestion. Simulated intestinal digestion did not further reduce the inhibitory activity significantly.
- Table 18 shows the dose response relationship of the digested St. John's Wort reference and reduced serotonin re-uptake.
- the data represents the mean radioactivity counts of four - replicate readings per sample and student's T-test statistical analysis (P) for significant activity versus the matched control. Similar tests of inhibition of dopamine re-uptake can be performed.
- Assay for inhibition of 5 ⁇ -reductase activity by detection of androgen metabolism For each saw palmetto sample to be tested, the material was diluted to the desired concentration (50 ⁇ g/ml saw palmetto extract) in 20 mM potassium phosphate buffer, pH 7.0. 20 ⁇ l of microsomes (enzyme) followed by testosterone (25 ⁇ g/ml final concentration) and progesterone (20 ⁇ g/ml, final concentration). 5 ⁇ -reductase substrates were then added to reaction mixture. The enzymatic reaction was initiated with the addition of NADPH (490 ⁇ g/ml final concentration) and was incubated at 37°C for one hour. The samples were then prepared for HPLC analysis by ether extraction of substrates. Testosterone and progesterone peak areas were integrated, compared to testosterone and progesterone standards, and inhibition was calculated based on the amount of unmetabolized substrate remaining.
- Assay for inhibiton of 5 ⁇ -reductase by detection of formation of 5HT and transformation of androgen receptor A single multi-site assay is capable of modeling, in vitro, synergistic activity between inhibition of 5HT formation and inhibition of 5HT transformation of androgen receptor.
- the following mixture is used to assay for biological activity: recombinant 5-alpha reductase or microsomes containing 5-alpha reductase, cofactor NADPH, substrate testosterone in limiting concentration, cytosol or nuclear extract containing competent unliganded androgen receptor bound to HSP90, and biotinylated androgen response element DNA in limiting concentration.
- Other components may be added to the above listed components, where appropriate.
- the mixture is contacted with neutravidin, avidin, or streptavidin bound to an ELISA plate, whereby the biotinylated androgen response element DNA of the mixture is immobilized. Androgen receptor in the mixture, if transformed by 5HT, forms a complex with the androgen response element DNA and is thus immobilized. Unbound materials are washed away.
- the ELISA plate is contacted with anti-androgen receptor antibody, such that the antibody binds to the androgen response element-androgen receptor complex on the plate.
- the antibody and complex may be detected using any number of techniques known in the art.
- the antibody may be labeled with an enzyme or a fluorescent tag or other detectable moiety.
- a second antibody i.e. anti-antibody coupled to alkaline phosphatase enzyme
- alkaline phosphatase is bound to the antibody and complex bound to the plate.
- Alkaline phosphatase is detected enzymatically using para nitrophenyl phosphate (PNPP) and measured colorimetrically in an ELISA plate reader.
- PNPP para nitrophenyl phosphate
- the activity of the Saw Palmetto containing reaction less the negative control divided by positive control less the negative control gives percent inhibition of the Saw Palmetto extract, and several doses within the range of the assay are used to estimate the IC 50 .
- compositions of Saw Palmetto are tested for their ability to inhibit prostaglandin E 2 (PGE 2 ) production by macrophage cells stimulated with interferon- ⁇ (IFN- ⁇ ).
- IFN- ⁇ interferon- ⁇
- RAW264.7 macrophage cells (ATCC, Rockville, MD) were propagated in DMEM (Gibco, Long Island, NY) supplemented with 2 mM L-glutamine (Gibco), 10% fetal bovine serum
- IFN- ⁇ (Gibco). Indomethacin (Sigma, St. Louis, MO), a known synthetic cyclooxygenase inhibitor, was used as a positive control for this methodology.
- the amount of PGE 2 produced was quantified by assaying PGE 2 levels in the tissue culture media using a quantitative PGE 2 ELISA Kit (Oxford Biomedical Research, Oxford, MI) in conjunction with a standard curve containing known PGE 2 concentrations diluted into tissue culture media.
- Table 20 shows the dose response relationship for three concentrations of digested Saw Palmetto reference material or indomethacin and PGE 2 production by RAW264.7 . macrophages stimulated with IFN- ⁇ .
- Test samples were prepared in phosphate buffered saline (PBS) to a concentration of 60 mg/ml or subjected to the simulated digestion protocol as described in Example 1, with the exception that the amount of ginseng test material used yielded a final concentration of ginseng extract of 50 mg/ml.
- the test material(s) or PBS vehicle control were administered by intraperitoneal injection at a dose of 50 mg ginseng extract/100 gram animal body weight using 5 animals/treatment group.
- One hour post-dosing blood plasma was produced and levels of corticosterone were determined using the quantitative RIA.
- Statistical analysis was via students T-test. Table 22 shows typical results obtained with these procedures.
- the statistical significance (P) is relative to the saline control. The data demonstrate that the corticosterone activity survives simulated digestion, and is functional in vivo.
- RAW264.7 macrophage cells (ATCC, Rockville, MD) were propagated in DMEM (Gibco, Long Island, NY) supplemented with 2 mM L-glutamine (Gibco), 10% fetal bovine serum (Gemini, Carlsbad, CA) and 1% penicillin/streptomycin solution. Cells were passaged at a cell density of 10 6 cells/ml and used at this same cell number for all experiments. RAW264.7 cells were inoculated into 96-well tissue culture plates (100 ⁇ l/well).
- Test cells were incubated with and without ginseng preparations prepared by simulated digestion as in Example 1, and simultaneously stimulated for induction of nitric oxide production with 10 units/ml IFN- ⁇ [Source?].
- Progesterone (Sigma, St. Louis, MO) was used as a positive control. (Miller et al, 1996).
- the amount of nitric oxide produced was quantified by assaying for nitric oxide by-product, nitrites in the tissue culture media using the Griess reagent (Sigma, St. Louis, MO) (Miller et al, 1996) in conjunction with a standard curve containing known micromolar amounts of nitrites in tissue culture media.
- Table 23 shows the dose-response relationship for three different doses between digested
- Ginseng material or progesterone control and inhibition of production of nitric oxide were also tested by the method described in Example 3. Doses up to 400 ⁇ g/mL displayed no direct free radical scavenging activity indicating that reduction in levels of nitric oxide was most likely due to inhibition of nitric oxide production.
- Table 24 shows the lot-to-lot reproducibility of inhibition of nitric oxide production for a set concentration of digested ginseng reference material of 200 ⁇ g/ml. The 5 lots tested showed some variability in activity, but overall this variability was low ⁇ 10% (based on relative standard deviation, %CV).
- Platelet-activating factor is a synapse messenger and amodulator of gene expression in the nervous system. Neurochem. Int. 26:435-441.
- Amyloid beta peptide induces necrosis rather than apoptosis. Brain Res. 645:253-264.
- Glucocorticoids inhibit the induction of nitric oxide synthase in macrophages. Biochem. Biophys. Res. Commun. 172:1246-1252.
- Miller-Dieker lissencephaly gene encodes a subunit of brain platelet-activating factor acetylhydrolase.
- Ginkgo biloba extract protects brain neurons against oxidative stress induced by hydrogen peroxide. Brain Res. 712:349-352.
- Ginsenoside-Rhl and Rh2 inhibit the induction of nitric oxide synthesis in murine peritoneal macrophages. Biochem. Mol. Biol. Int. 40:751-757.
- Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc. Natl. Acad. Sci. USA 87:10043-10047.
- Flavonoids are scavengers of superoxide anions. Biochem. Pharmacol. 37:837-841.
- Nitric oxide protects against cellular damage and cytotoxicity from reactive oxygen species. Proc. Natl. Acad. Sci. USA 90:9813-9817.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU49956/99A AU4995699A (en) | 1998-07-14 | 1999-07-14 | Method for identifying and confirming consistent bio-functionality of natural compositions |
EP99934036A EP1105146A1 (en) | 1998-07-14 | 1999-07-14 | Method for identifying and confirming consistent bio-functionality of natural compositions |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9268698P | 1998-07-14 | 1998-07-14 | |
US60/092,686 | 1998-07-14 | ||
US9436098P | 1998-07-28 | 1998-07-28 | |
US60/094,360 | 1998-07-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000003725A1 true WO2000003725A1 (en) | 2000-01-27 |
Family
ID=26785943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/015957 WO2000003725A1 (en) | 1998-07-14 | 1999-07-14 | Method for identifying and confirming consistent bio-functionality of natural compositions |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1105146A1 (en) |
CN (1) | CN1317974A (en) |
AU (1) | AU4995699A (en) |
WO (1) | WO2000003725A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU779424B2 (en) * | 1998-10-23 | 2005-01-27 | Yale University | Phytomics: a genomic-based approach to herbal compositions |
WO2008141392A1 (en) * | 2007-05-24 | 2008-11-27 | Murray Goulburn Co-Operative Co. Limited | Use of a bioassay to validate efficacy |
US8096230B2 (en) | 2007-03-15 | 2012-01-17 | Shalom Levin | Brewing element with a central inlet |
WO2012142413A2 (en) * | 2011-04-14 | 2012-10-18 | Theravasc Inc. | Nitrite compositions and uses thereof |
US9561249B2 (en) | 2013-02-20 | 2017-02-07 | Theravasc Inc. | Pharmaceutical formulations of nitrite and uses thereof |
US9579344B2 (en) | 2009-06-18 | 2017-02-28 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Use of nitrite salts in treating tissue damage |
US9649334B2 (en) | 2007-11-15 | 2017-05-16 | The Uab Research Foundation | Use of nitrite salts in chronic ischemia |
CN106841387A (en) * | 2017-02-17 | 2017-06-13 | 上海海洋大学 | A kind of preparation and application of the mesoporous silicon sphere surface acoustic wave sensor based on functionalization |
US10307441B2 (en) | 2009-10-14 | 2019-06-04 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Pharmaceutical formulations of nitrite and uses thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101968480B (en) * | 2009-10-27 | 2013-09-11 | 闽南师范大学 | Simulation and detection method for content of microelements in medicine capable of being absorbed by human body |
CN102680654B (en) * | 2011-12-19 | 2014-10-15 | 河南科技大学 | Method for building model for collectively evaluating bioavailability and toxicity of cadmium accumulation in food for human body |
-
1999
- 1999-07-14 EP EP99934036A patent/EP1105146A1/en not_active Withdrawn
- 1999-07-14 AU AU49956/99A patent/AU4995699A/en not_active Abandoned
- 1999-07-14 CN CN 99810878 patent/CN1317974A/en active Pending
- 1999-07-14 WO PCT/US1999/015957 patent/WO2000003725A1/en not_active Application Discontinuation
Non-Patent Citations (6)
Title |
---|
HIDALGO I., ET AL.: "Carrier Mediated Transport and Efflux Mechanisms in Caco-2 Cells", ADVANCED DRUG DELIVERY REVIEWS, vol. 22, no. 1-2, 15 November 1996 (1996-11-15), pages 53 - 66, XP002925053 * |
HOBBS C: "HANDBOOK FOR HERBAL HEALING, PASSAGE", HANDBOOK FOR HERBAL HEALING, XX, XX, 1 October 1990 (1990-10-01), XX, pages 29 - 33, XP002925049 * |
RANALDI G., ET AL.: "Epithelial Cells in Culture as a Model for the Intestinal Transport of Antimicrobial Agents", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 36, no. 7, July 1992 (1992-07-01), pages 1374 - 1381, XP002925052 * |
ROSSI G V: "BIOLOGICAL TESTING", REMINGTON'S PHARMACEUTICAL SCIENCES, MACK PUBLISHING CO., US, no. 16, 1 January 1980 (1980-01-01), US, pages 520 - 531, XP002925048 * |
VAN BREEMEN R., ET AL.: "Degradation of Peptide Drugs by Immobilized Digestive Proteases", DRUG METABOLISM AND DISPOSITION, vol. 19, no. 3, 1991, pages 683 - 690, XP002925050 * |
WALGREN R., ET AL.: "Transport of Quercetin and its Glucosides Across Human Intestinal Epithelial Caco-2 Cells", BIOCHEMICAL PHARMACOLOGY, vol. 55, no. 10, 10 May 1998 (1998-05-10), pages 1721 - 1727, XP002925051 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU779424B2 (en) * | 1998-10-23 | 2005-01-27 | Yale University | Phytomics: a genomic-based approach to herbal compositions |
US8096230B2 (en) | 2007-03-15 | 2012-01-17 | Shalom Levin | Brewing element with a central inlet |
WO2008141392A1 (en) * | 2007-05-24 | 2008-11-27 | Murray Goulburn Co-Operative Co. Limited | Use of a bioassay to validate efficacy |
US9649334B2 (en) | 2007-11-15 | 2017-05-16 | The Uab Research Foundation | Use of nitrite salts in chronic ischemia |
US10864229B2 (en) | 2007-11-15 | 2020-12-15 | Board Of Supervisors Of Louisiana State University | Use of nitrite salts in chronic ischemia |
US10596188B2 (en) | 2009-06-18 | 2020-03-24 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Use of nitrite salts in treating tissue damage |
US9579344B2 (en) | 2009-06-18 | 2017-02-28 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Use of nitrite salts in treating tissue damage |
US10307441B2 (en) | 2009-10-14 | 2019-06-04 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Pharmaceutical formulations of nitrite and uses thereof |
US10463689B2 (en) | 2009-10-14 | 2019-11-05 | Board Of Supervisors Of Louisiana State University | Pharmaceutical formulations of nitrite and uses thereof |
WO2012142413A3 (en) * | 2011-04-14 | 2012-12-06 | Theravasc Inc. | Nitrite compositions and uses thereof |
WO2012142413A2 (en) * | 2011-04-14 | 2012-10-18 | Theravasc Inc. | Nitrite compositions and uses thereof |
US9561249B2 (en) | 2013-02-20 | 2017-02-07 | Theravasc Inc. | Pharmaceutical formulations of nitrite and uses thereof |
CN106841387A (en) * | 2017-02-17 | 2017-06-13 | 上海海洋大学 | A kind of preparation and application of the mesoporous silicon sphere surface acoustic wave sensor based on functionalization |
Also Published As
Publication number | Publication date |
---|---|
CN1317974A (en) | 2001-10-17 |
EP1105146A1 (en) | 2001-06-13 |
AU4995699A (en) | 2000-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Colalto | Herbal interactions on absorption of drugs: Mechanisms of action and clinical risk assessment | |
Choi et al. | Screening of Indonesian medicinal plants for inhibitor activity on nitric oxide production of RAW264. 7 cells and antioxidant activity | |
Nahata et al. | Anxiolytic activity of Evolvulus alsinoides and Convulvulus pluricaulis in rodents | |
Elisia et al. | Comparison of RAW264. 7, human whole blood and PBMC assays to screen for immunomodulators | |
EP1047936A1 (en) | Pharmaceutical grade saw palmetto, senenoa repens | |
WO2000003725A1 (en) | Method for identifying and confirming consistent bio-functionality of natural compositions | |
Dog et al. | Assessing safety of herbal products for menopausal complaints: An international perspective | |
Rasheed et al. | Involvement of monoamines and proinflammatory cytokines in mediating the anti-stress effects of Panax quinquefolium | |
Chaturvedi et al. | Plant secondary metabolites for preferential targeting among various stressors of metabolic syndrome | |
Koffuor et al. | Effect of ethanolic stem bark extract of blighia unijugata (sapindaceae) on monosodium glutamate-induced uterine leiomyoma in Sprague-Dawley rats | |
WO1999021008A1 (en) | Pharmaceutical grade garlic | |
Park et al. | 4-Hydroxycinnamic acid attenuates neuronal cell death by inducing expression of plasma membrane redox enzymes and improving mitochondrial functions | |
JP2002525080A (en) | Method for determining the activity of complex mixtures | |
WO1999020292A1 (en) | Pharmaceutical grade ginseng | |
JP2002515402A (en) | Pharmaceutical grade ginkgo | |
Muhammad et al. | Hypoglycemic and hypolipidemic properties of Casuarina equisetifolia leaf extracts in alloxan induced diabetic rats | |
Pawar et al. | Antidepressant effect of Hedyotis corymbosa extract in olfactory bulbectomy rats | |
Sarfaraz et al. | Comparative evaluation of hypolipidemic effects of ethanolic extract of fruit of Piper chaba and Piper nigrum on albino rabbits | |
Stein et al. | Complementary and alternative cardiovascular medicine | |
Farooqi et al. | Antihyperlipidemic and hepatoprotective effect of Cucurbita maxima (Duch) seed in paracetamol induced hepatotoxicity and high fat diet-induced hypercholesterolemic rats. | |
Tejavathi et al. | Phytochemical Quantification and Antioxidant Potential of Curcuma karnatakensis [White turmeric]–An endemic taxon | |
Kirakosyan et al. | The use of selected medicinal herbs for chemoprevention and treatment of cancer, Parkinson’s disease, heart disease, and depression | |
El-Hawary et al. | Extracts of Different Organs of Macadamia Nut Tree (Macadamia Integrifolia) Ameliorate Oxidative Damage in D-Galactose Accelerated Aging Model in Rats | |
Bala Surya | In Silico and In Vitro Aldose Reductase Inhibition and In Vivo Activity against Galactose-Induced Cataractogenesis in Rats By Momordica Charantia L. Fruits | |
Pratap Singh et al. | Anti-obesity potential of bioactive guided fractions of A nnona squamosa linn. leaves extract: a combination of in-vitro, in-vivo and in-silico studies along with profiling of lead compounds by HPTLC MS-MS n method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99810878.2 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999934036 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1999934036 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999934036 Country of ref document: EP |